top of page


Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
22/09/2026 Amgen reported positive Phase 3 results for dazodalibep in moderate-to-severe systemic sjögren's disease AbbVie’s RINVOQ® received EU approval for children with active pJIA Amgen reported positive Phase 3 results for dazodalibep in moderate-to-severe systemic sjögren's disease (Ref) Amgen’s Ph3 OASIZ 301 trial of dazodalibep (CD40L antagonist) met its primary endpoint, demonstrating statistically significant and clinically meaningful improvement in systemic disease
decodeMR Team
Sep 231 min read


Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
14/07/2026 Innovent Biologics and Spero Therapeutics announced an exclusive licensing agreement for IBI355 for the treatment of immune-mediated diseases Innovent Biologics and Spero Therapeutics announced an exclusive licensing agreement for IBI355 for the treatment of immune-mediated diseases (Ref) Innovent Biologics and Spero Therapeutics announced an exclusive license agreement for IBI355 (SP001; a third-generation Fc-silent anti-CD40L antibody) for immune-mediated disease
decodeMR Team
Jul 161 min read
bottom of page